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Abstract Yersinia enterocolitica infections are common in
humans. However, very scarce data are available on the
different biotypes and virulence factors of human strains,
which has proved to be problematic to assess the clinical
significance of the isolated strains. In this study, the
presence of the ail gene and distribution of different bio-
and serotypes among human Y. enterocolitica strains and
their possible relation to the genotype and antimicrobial
resistance were studied. In total, 128 Y. enterocolitica
strains isolated from human clinical samples in Switzerland
during 2001–2010 were characterised. Most (75 out of 128)
of the Y. enterocolitica strains belonged to biotypes 2, 3 or
4 and carried the ail gene. One of the 51 strains that
belonged to biotype 1A was also ail positive. Most of the
ail-positive strains belonged to bioserotype 4/O:3 (47 out of
76) followed by 2/O:9 (22 out of 76). Strains of bioserotype
4/O:3 were dominant among patients between 20 and
40 years old and strains of biotype 1A dominate in patients
over 40 years. Strains belonging to biotypes 2, 3 and 4,
which all carried the ail gene, exhibited a high homogeneity
with PFGE typing. Y. enterocolitica 2/O:5,27 and 2/O:9
strains showed resistance to amoxicillin/clavulanic acid and
cefoxitin, but Y. enterocolitica 4/O:3 strains did not.
Introduction
Yersiniosis is a zoonotic bacterial disease with high public
health relevance, especially in Europe because of its high
incidence [1]. It is the third most frequently reported
bacterial enteric disease after campylobacteriosis and
salmonellosis in most European countries [2]. Human
illness is mainly caused by Yersinia enterocolitica, which
includes strains of diverse pathogenicity. Y. enterocolitica
strains belonging to biotypes 1B and 2–5 are considered
pathogenic, whereas strains belonging to biotype 1A are in
general considered non-pathogenic. Pathogenicity can also
be determined by PCR methods detecting different viru-
lence genes [3]. Further characterisation of pathogenic Y.
enterocolitica strains is still frequently determined by
pulsed-field gel electrophoresis (PFGE). The PFGE types
have been shown to correlate with biotype [4].
Y. enterocolitica is considered to be an important food-
borne pathogen. Infection is most often acquired by eating
raw or undercooked pork [3]. Rarely, this organism is
transmitted through contaminated blood during a transfusion.
Common symptoms of food-borne infections are diarrhoea,
abdominal pain and fever, but sequelae, such as joint pain
(reactive arthritis) and skin rash (erythema nodosus), are not
uncommon [1, 5]. Infection with Y. enterocolitica occurs
most often in young children [2].
Uncomplicated yersiniosis usually resolves on its own
without antimicrobial treatment. However, in more severe
cases, like septicaemia or focal extra-intestinal infection,
and in immune-compromised patients, medication may be
required. Y. enterocolitica is a β-lactamase producer and
thus is resistant to ampicillin and first-generation cephalo-
sporins, but it is mostly susceptible to other antimicrobials,
such as aminoglycosides, tetracyclines, trimethoprim-
sulfamethoxazole and fluoroquinolones, that are used for
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therapy. Multi-drug-resistant strains, which are resistant to
streptomycin, sulfonamides, tetracycline and /or nalidixic
acid, have occasionally been reported among some Y.
enterocolitica strains [6].
The most commonly reported serotype of Y. enter-
ocolitica strains isolated from human cases in Europe is
O:3 and less commonly O:9 [2]. However, very scarce
data on the virulence genes and the distribution of
different biotypes among human strains are available. In
this study, human Y. enterocolitica strains isolated during
2001 to 2010 in Switzerland were characterised to obtain
information about the ail gene, and bio- and serotypes
present in human clinical strains. Furthermore, the strains
were genotyped and the antimicrobial resistance was
studied.
Materials and methods
In total, 128 Y. enterocolitica strains collected from human
patients in Switzerland during 2001 to 2010 were charac-
terised (Table 1). Most of the strains (94%) were from
humans suffering from diarrhoea, 4 strains were from
blood, 2 from liver, 1 each from gall bladder, ulcer and
abscess. Y. enterocolitica strains were almost equal in
number in female (62) and male (63) patients. Only 6
strains (5%) were from patients under 6 years of age, but 28
strains (22%) were from patients over 60 (Table 1). Six
patients reported having travelled abroad before infection.
All 128 Y. enterocolitica strains were biotyped and
serotyped. The biotype was determined using pyrazinamidase
and tween activity, esculin hydrolysis, indole production, and
salicin, xylose and trehalose fermentation [4]. Serotyping was
carried out with slide agglutination using commercial Y.
enterocolitica O:3, O:5, O:9 and O:27 antisera (Sifin, Berlin,
Germany). PCR was used to detect the ail gene located in
the chromosome of pathogenic Y. enterocolitica strains
according to Thoerner et al. [7].
All strains were genotyped with pulsed field gel
electrophoresis (PFGE) according to the PulseNet protocol
(http://www.cdc.gov/pulsenet/protocols/yersinia_Apr2006.
pdf) using restriction enzyme XbaI (New England Biolabs,
Beverly, MA). DNA fragments were separated with a
CHEF-DR III system (Bio-Rad, Hercules, CA, USA) using
pulse times ranging from 5 to 40 s for 19 h at an angle
of 120°C. Salmonella enterica serovar Braenderup H9812
(New England Biolabs) was used as the standard. GelCompar
II software (Applied Maths NV, Sint–Martens–Latem,
Belgium) was used for pattern comparison. PFGE patterns
were considered clonally related if they had a similarity
coefficient >80%, optimisation 0.5% and tolerance 2.5% (the
Dice similarity index and the unweighted pair group method
with the arithmetic mean).
Antimicrobial resistance analysis was performed by
the disc diffusion test according to the Clinical and
Laboratory Standards Institute (2009). Fourteen antimi-
crobials were tested: ampicillin (10 μg), amoxicillin/
clavulanic acid (20/10 μg), cefalothin (30 μg), cefoxitin
(30 μg), cefpodoxim (10 μg), ceftazidime (30 μg), cefuroxime
(30 μg), ciprofloxacin (5 μg), gentamicin (10 μg), kanamycin
(30 μg), nalidixic acid (30 μg), streptomycin (10 μg),
tetracycline (30 μg) and trimethoprim/sulfamethoxazole
(1.25/23.75 μg). The reference strain Escherichia coli ATCC
25922 was used as the quality control.
Results
About 60% (75 out of 128) of the human Y. enterocolitica
strains isolated from clinical samples belonged to biotypes
Table 1 Y. enterocolitica strains by gender and age collected during 2001 and 2010 in Switzerland from human clinical samples
Number
of strains
Year Gender Age (years)
Female patients Male patients NK <6 6–20 21–40 41–60 >60 NK
5 2001–2002 2 2 1 0 1 1 0 2 1
14 2003 7 7 0 1 0 3 8 2 0
12 2004 6 6 0 1 2 3 2 4 0
19 2005 5 14 0 0 2 7 4 6 0
21 2006 10 10 1 2 2 7 5 5 0
14 2007 9 5 0 0 4 2 4 4 0
11 2008 7 4 0 0 0 6 3 2 0
12 2009 6 5 1 0 3 6 2 0 1
20 2010 10 10 0 2 1 10 3 3 0
128 2001–2010 62 63 3 6 15 45 32 28 2
NK = not known
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2, 3 or 4 which are considered to be pathogenic to humans
(Table 2). However, a high number (51 out of 128, 40%) of
Y. enterocolitica strains belonged to biotype 1A, which is
regarded as non-pathogenic. The dominant pathogenic
bioserotype was 4/O:3 (37%) followed by 2/O:9 (17%).
Only 4 strains belonged to bioserotype 2/O:5,27 and 2 to
bioserotype 3/O:3. Two strains did not belong to any of the
known biotypes.
The ail gene was studied by PCR and it was detected in
all 75 strains belonging to pathogenic bioserotypes
2/O:5,27, 2/O:9, 3/O:3 and 4/O:3. Surprisingly, ail was
also detected in one strain belonging to non-pathogenic
biotype 1A. This strain was isolated in 2007 from the
faeces of a 62-year-old woman. Both strains of unknown
biotype were ail negative. They were isolated from the
faeces of a 40-year-old woman and a 50-year-old man in
2005. The two strains, which were not of any known
biotype, were ail negative and pyrazinamidase positive, and
thus were regarded as non-pathogenic Y. enterocolitica-like
strains.
More Y. enterocolitica strains of biotype 1A and
bioserotype 2/O:9 were from female than from male
patients (Table 2). Strains belonging to bioserotype 4/O:3
were more frequently from males than from female patients.
Y. enterocolitica of bioserotype 4/O:3 was isolated more
often from patients between 0 and 40 years of age (29) than
from patients over 40 (17; Table 2). Biotype 1A strains
were the most common type in patients over 40 and they
were frequently (18 out of 27, 67%) isolated from female
patients.
Eight Y. enterocolitica strains were isolated from extra-
intestinal sites: blood (4), liver (2), gall bladder (1), ulcer
(1) and abscess (1). Strains of bioserotype 4/O:3 were
isolated twice from blood and once from liver and ulcer.
The 2 strains of bioserotype 2/O:9 were isolated from
blood. Surprisingly, 2 strains belonging to biotype 1A were
from extra-intestinal sites: the gall bladder and an abscess.
All 128 Y. enterocolitica strains were sensitive to
ceftazidim (30 μg), ciprofloxacin (5 μg) and gentamycin
(10 μg), and resistant to ampicillin (10 μg) and cefalothin
Table 2 Y. enterocolitica strains of different bioserotypes according to gender and age
Bioserotype Number of strains (%) Gender Age
Female Male NK <6 6–20 21–40 41–60 >60 NK
1A 51 (40) 29 21 1 1 7 15 14 13 1
2/O:5,27 4 (3) 2 2 0 1 0 1 1 1 0
2/O:9 22 (17) 13 9 0 1 2 7 4 8 0
3/O:3 2 (2) 0 2 0 0 1 1 0 0 0
4/O:3 47 (37) 17 28 2 3 5 21 11 6 1
NT 2 (2) 1 1 0 0 0 1 1 0 0
NK = not known; NT = not typeable
Table 3 Number of Y. enter-
ocolitica strains showing resis-
tance to antimicrobial agents
NT = not typeable;
I = intermediate; R = resistant
Antimicrobial agent Bioserotype (number of strains)
1A (51) 2/O:5,27 (4) 2/O:9 (22) 3/O:3 (2) 4/O:3 (47) NT (2)
I R I R I R I R I R I R
Ampicillin 0 51 0 4 0 22 0 2 0 47 0 2
Amoxicillin/clavulanic acid 4 47 1 3 3 18 0 2 7 0 0 2
Cefalothin 0 51 0 4 0 22 0 2 0 47 0 2
Cefoxitin 22 23 0 4 3 18 0 2 0 0 1 1
Cefpodoxim 16 4 1 1 4 2 2 0 1 0 0 0
Cefuroxime 7 0 0 0 13 0 2 0 5 0 0 0
Kanamycin 0 3 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 0 1 0 0 0 0 0 0 0 2 0 0
Streptomycin 3 0 0 0 0 0 1 0 5 7 0 0
Tetracycline 0 0 0 0 0 0 0 0 1 0 0 0
Trimethoprim/sulfa 0 0 0 0 0 0 0 0 2 1 0 0
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(30 μg). Several strains were resistant to amoxicillin/
clavulanic acid (20/10 μg) and cefoxitin (30 μg; Table 3).
Interestingly, most strains belonging to bioserotypes
2/O:5,27 (3–4/4), 2/O:9 (18/22) and 3/O:3 (2/2) were
resistant to amoxicillin/clavulanic acid and cefoxitin, but
all 47 strains belonging to bioserotype 4/O:3 were sensitive
to these agents. Sporadic resistance occurred to cefpodoxim
(10 μg), kanamycin (30 μg), nalidixic acid (30 μg),
streptomycin (10 μg) and trimethoprim/sulfamethoxazole
(1.25/23.75). Strains belonging to bioserotypes 2/O:5,27
and 2/O:9 showed resistance cefpodoxim and strains of
bioserotype 4/O:3 to streptomycin, nalidixic acid and
trimethoprim/sulfamethoxazole (Table 3). Only 1 multi-
drug resistant strain was detected. This strain was belonging
to bioserotype 4/O:3 and it was isolated in year 2006
from the faeces of a 27-year old woman. It showed
resistance to nalidixic acid, streptomycin and trimethoprim/
sulfamethoxazole.
All 128 Y. enterocolitica strains were characterised by
PFGE using the XbaI restriction enzyme. Strains belonging
to bioserotypes 2/O:5,27 (2), 2/O:9 (22), 3/O:3 (2) and
4/O:3 (47) showed very limited genetic diversity; however,
Fig. 1 Dendrogram of Y. enter-
ocolitica strains belonging to
biotypes 2, 3 and 4
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each bioserotype differed clearly from all the others
(Fig. 1). The 51 strains belonging to biotype 1A were very
heterogeneous (Fig. 2). The ail-positive biotype 1A strain
was grouped among the other biotype 1A strains (Fig. 2)
and differed clearly from strains belonging to bioserotypes
2/O:5,27, 2/O:9, 3/O:3 and 4/O:3.
Discussion
Most of the human Y. enterocolitica strains belonged to the
bioserotypes associated with human disease (75 out of
128). All these strains belonging to bioserotypes 2/O:5,27,
2/O:9, 3/O:3 and 4/O:3 were ail positive. The ail gene
codes the Ail protein, which is involved in the attachment
and invasion of the host cells and in the serum resistance of
pathogenic Y. enterocolitica strains [8]. Bioserotype 4/O:3
was the most frequently identified pathogenic type (47 out
of 75, 63%); however, the prevalence of bioserotype 2/O:9
(22 out of 75, 30%) was surprisingly high. Only 4 strains
(5%) belonged to bioserotype 2/O:5,27 and 2 (3%) to
bioserotype 3/O:3. In the last annual report of the European
Centre for Disease Prevention and Control (ECDC),
8 European countries provided data on serotype; the two
most common serotypes were O:3 (91%) and O:9 (7%) [2].
In Germany, of all the notified human cases with
information on serotype, 89% were attributed to serotype
O:3, and only 6% to serotype O:9 and 0.8% to serotype
O:5,27 [1].
Only 6 (5%) patients reported having travelled abroad
before infection, which indicates that the infections are
domestically acquired. The majority (> 90%) of yersiniosis
cases in Europe have also been reported to be domestically
acquired [1, 2]. In Switzerland, pigs at slaughter have been
shown to carry ail-positive Y. enterocolitica bioserotype
4/O:3 frequently in the tonsils [4], which shows that
domestic pigs can be an important source of human
bioserotype 4/O:3 infection in Switzerland. Pigs have been
shown to be an important reservoir and pork an important
source of human Y. enterocolitica 4/O:3 infection in
Germany and Finland [9]. Bioserotypes 2/O:5,27 and
2/O:9 have been sporadically isolated from Swiss pigs
and could thus also be the source of human infections.
However, the prevalence of bioserotype 2/O:9 was high in
human infections, which indicates that there may be
infection sources other than pigs. Two human strains
belonged to bioserotype 3/O:3, which can indicate an
Asiatic origin because this bioserotype is mainly reported
in Asia [10]. However, bioserotype 3/O:3 has also been
sporadically isolated from chinchillas in Europe [11].
Some of the Y. enterocolitica strains belonging to
bioserotypes 2/O:9 and 4/O:3 (6 out of 69) were isolated
from extra-intestinal sites. Extra-intestinal infections are
rare and usually described in humans who are immune-
compromised or in those with iron overload [12]. Y.
enterocolitica 4/O:3 was isolated once from liver and skin
lesions. Two strains of type 2/O:9 (9%) and 4/O:3 (4%)
were isolated from blood, showing that these bioserotypes
are not uncommon causes of bacteraemia in humans. Y.
enterocolitica was one of the first recognised causes of
post-transfusion sepsis [13]. Serotypes O:3 and O:9 are the
most common types attributed to post-transfusion septic
shock. Because Yersinia has the property to grow at 4°C,
the low number of Y. enterocolitica strains collected from
asymptomatic donors can lead to a high bacterial load if the
blood products are stored for some weeks.
Y. enterocolitica strains belonging to biotype 1A are
considered non-pathogenic to humans because they lack the
major virulence determinants [14]. However, the number of
strains belonging to biotype 1A was high (40%) among
Fig. 1 (continued)
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human patients in Switzerland. In Finland, an even higher
prevalence (64%) of strains belonging to this biotype was
recently reported [15]. One reason might be that in Finland,
but not in Switzerland, cold enrichment, which increases the
number of biotype 1A strains, is frequently used for human
clinical samples. Y. enterocolitica strains belonging to biotype
1A lack the ail gene, which is an important chromosomal
virulence gene found only in strains belonging to biotypes 1B
and 2–5. Surprisingly, 1 of 51 strains of biotype 1A (2%) was
ail-positive. Recently, Sihvonen et al. reported 1 ail-positive
strain among 299 human clinical Y. enterocolitica biotype 1A
strains, which shows that the ail gene is not a common
finding among clinical biotype 1A strains [16].
Y. enterocolitica biotype 1A strains were mostly (49 out
of 51) isolated from faeces. Surprisingly, Y. enterocolitica
biotype 1A strains were also isolated from the gall bladder
and from skin lesions. The clinical disease with which Y.
enterocolitica biotype 1A has been reported to be associ-
ated is enteritis [17]. Biotype 1A strains have previously
been isolated from blood, but not from other extra-intestinal
sites. However, the pathogenic potential and true public
health significance of Y. enterocolitica biotype 1A strains
are still unclear [17].
The highest notification rate has been in children under
5 years of age in Europe followed by the age group 5–
14 years [2]. However, Y. enterocolitica was seldom
isolated from young children under 6 years of age (6 out
of 128) and from patients between 6 and 20 (15 out of 128)
in Switzerland. One reason might be the high number of
biotype 1A strains that were commonly found in patients
(ail positive)
Fig. 2 Dendrogram of Y. enter-
ocolitica strains belonging to
biotype 1A
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over 20 years of age. In a recent study, the symptoms of the
patients with Y. enterocolitica biotype 1A differed from
yersiniosis caused by the pathogenic biotypes [5]. Patients
infected with pathogenic biotype strains were younger
(mean age: 32 years and 50 years respectively), had fever
(67% and 35% respectively) and reactive arthritis more
often (10% and 3% respectively) than those with biotype
1A strains, which suggests the lacking virulence of biotype
1A strains. However, more research is needed to study the
potential pathogenicity of biotype 1A strains.
Bioserotype 4/O:3 strains were more often isolated from
male (28 out of 47) than from female patients (17 out of 47). In
Germany, where strains of biotype 4/O:3 strain dominate, the
infections occurred more frequently in boys and men than in
girls and women [1]; however, there was no explanation for
this phenomenon. Surprisingly, biotype 1A strains were more
often found in female patients, especially in women over 40,
than in male patients. One explanation for the higher
prevalence of biotype 1A strains among women over 40
might be that they visit the doctor more frequently than men.
Human Y. enterocolitica strains showed susceptibility to
most antimicrobials other than β-lactams. All strains were
susceptible to ceftazidime, ciprofloxacin and gentamicin and
only sporadically resistant to cefpodoxim, kanamycin, nali-
dixic acid, streptomycin and trimethoprim/sulfamethoxazole.
Interestingly, most of the biotype 2 and 3 strains were resistant
to amoxicillin/clavulanic acid and cefoxitin when all biotype
4/O:3 strains were sensitive, indicating an association between
susceptibility to amoxicillin/clavulanic acid and cefoxitin
and biotype. Only one strain, which belonged to
bioserotype 4/O:3, showed resistance to multiple microbial
agents: streptomycin, nalidixic acid and trimethoprim/
sulfamethoxazole. Multi-resistance has been shown to be
rare among Y. enterocolitica strains in Switzerland and
Germany [18, 19]. In a recent study from Finland, multi-
resistance was significantly associated with travelling abroad
[6]. Surprisingly, 3 Y. enterocolitica strains (1 biotype 1A
and 2 biotype 4/O:3 strains) were resistant to nalidixic acid,
which has not been reported before in Switzerland.. It has
been shown that nalidixic acid resistance correlates with
decreased susceptibility to ciprofloxacin in MIC determina-
tion [6], which can be problematic in the treatment of
complicated yersiniosis cases.
All strains were characterised with PFGE using XbaI.
This restriction enzyme was used in the PulseNet protocol
and in an earlier Swiss study [19]. PFGE with XbaI
distinguished the different biotypes from each other and
can thus help to identify ail-positive Y. enterocolitica strains
of different biotypes. Strains belonging to biotypes 2, 3 and
4, which all carried the ail gene, exhibited high homoge-
neity. However, strains belonging to serotypes O:5,27 and
O:9 of biotype 2 could also easily be differentiated from
each other. Strains belonging to biotype 1A, including the
one ail-positive strain, appeared to be highly heteroge-
neous. High genetic diversity among biotype 1A strains has
also been demonstrated by amplified fragment length
polymorphism (AFLP) typing [20]. High genetic diversity
is a common feature among non-pathogenic, environmental
bacteria when most of the pathogenic bacteria are usually
genetically monomorphic [21].
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